Mitophagy‐reporter Muller cell line (MQ‐MG2) as a novel platform for ocular drug discovery
Aims/Purpose: The controlled activation of mitophagy has emerged as an exciting therapeutic angle in the treatment of ocular conditions, including diabetic retinopathy and age‐related macular degeneration. Here, we report a novel Muller cell line (MQ‐MG2) for the rapid screening of mitophagy‐activat...
Gespeichert in:
| Veröffentlicht in: | Acta ophthalmologica (Oxford, England) England), 2024-01, Vol.102 (S279), p.n/a |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | S279 |
| container_start_page | |
| container_title | Acta ophthalmologica (Oxford, England) |
| container_volume | 102 |
| creator | Anderson, Aidan Bouzinab, Kaouthar Rudzinska, Paula Ganley, Ian Wallace, Graham Romero, Jose M. |
| description | Aims/Purpose: The controlled activation of mitophagy has emerged as an exciting therapeutic angle in the treatment of ocular conditions, including diabetic retinopathy and age‐related macular degeneration. Here, we report a novel Muller cell line (MQ‐MG2) for the rapid screening of mitophagy‐activating drugs.
Methods: MQ‐MG2 were cloned from spontaneously immortalized primary Muller cells (PMCs) derived from mitophagy reporter (Mito‐QC) mice. Muller glia characteristics were assessed by immunocytochemistry, western blotting, and metabolic flux (Seahorse). The versatility of MQ‐MG2 to detect mitophagy‐activating drugs was tested via pharmacological activation (PINK1‐dependent and PINK1‐independent) and further validated in vivo using Mito‐QC mice.
Results: MQ‐MG2 were expanded over 50 passages while retaining expression of Mito‐QC reporter. MQ‐MG2 showed key phenotypic markers of Muller glia, including glutamine synthetase, glial fibrillary acidic protein, Aquaporin 4, and Interleukin‐33. At the bioenergetic level, MQ‐MG2 showed lower basal‐ and ATP‐linked respiration than PMCs, while displaying superior reserve capacity (p |
| doi_str_mv | 10.1111/aos.16138 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_3089651189</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3089651189</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1378-acb98a21ffe3a4e5a58024d39e15fd4b047d612810458ea9711f4f0b5baa11e73</originalsourceid><addsrcrecordid>eNp1kMFKxDAQhoMouK4efIOAFz10N9M2bXpcFl2FLYuo4MmQtsnaJbupSav05iP4jD6J0Yo35zD_wHzzD_wInQKZgK-pMG4CCURsD40gpTSI0oTt_8308RAdObchJIEkiUfoKa9b0zyLdf_5_mFlY2wrLc47rb2UUmus653E5_mt3-eL8AILhwXemVepcaNFq4zdYt-wKTstLK5st8ZV7UpP2P4YHSihnTz51TF6uLq8n18Hy9XiZj5bBiVEKQtEWWRMhKCUjEQsqaCMhHEVZRKoquKCxGmVQMiAxJRJkaUAKlakoIUQADKNxuhs8G2seemka_nGdHbnX_KIsCyhACzz1MVAldY4Z6Xija23wvYcCP-Oj_v4-E98np0O7FutZf8_yGeru-HiCw9ectw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3089651189</pqid></control><display><type>article</type><title>Mitophagy‐reporter Muller cell line (MQ‐MG2) as a novel platform for ocular drug discovery</title><source>Wiley Online Library All Journals</source><creator>Anderson, Aidan ; Bouzinab, Kaouthar ; Rudzinska, Paula ; Ganley, Ian ; Wallace, Graham ; Romero, Jose M.</creator><creatorcontrib>Anderson, Aidan ; Bouzinab, Kaouthar ; Rudzinska, Paula ; Ganley, Ian ; Wallace, Graham ; Romero, Jose M.</creatorcontrib><description>Aims/Purpose: The controlled activation of mitophagy has emerged as an exciting therapeutic angle in the treatment of ocular conditions, including diabetic retinopathy and age‐related macular degeneration. Here, we report a novel Muller cell line (MQ‐MG2) for the rapid screening of mitophagy‐activating drugs.
Methods: MQ‐MG2 were cloned from spontaneously immortalized primary Muller cells (PMCs) derived from mitophagy reporter (Mito‐QC) mice. Muller glia characteristics were assessed by immunocytochemistry, western blotting, and metabolic flux (Seahorse). The versatility of MQ‐MG2 to detect mitophagy‐activating drugs was tested via pharmacological activation (PINK1‐dependent and PINK1‐independent) and further validated in vivo using Mito‐QC mice.
Results: MQ‐MG2 were expanded over 50 passages while retaining expression of Mito‐QC reporter. MQ‐MG2 showed key phenotypic markers of Muller glia, including glutamine synthetase, glial fibrillary acidic protein, Aquaporin 4, and Interleukin‐33. At the bioenergetic level, MQ‐MG2 showed lower basal‐ and ATP‐linked respiration than PMCs, while displaying superior reserve capacity (p < 0.001). Indicative of equivalent glycolytic profiles, extracellular acidification rates (baseline and stressed) remained comparable to PMCs. Importantly, MQ‐MG2 showed excellent sensitivity to screen for mitophagy‐activating drugs, including novel small‐molecules acting through (putative) PINK1‐independent pathways. The versatility of MQ‐MG2 as a drug discovery platform was validated in vivo, where oral administration of PINK1‐independent activator (PIA‐01) amplified mitophagy at the outer retina dose‐dependently.
Conclusions: MQ‐MG2 enables rapid and reliable detection of mitophagy‐activating drugs for ocular application. This platform overcomes the limitations of primary cultures, including variability due to cellular senescence and heterogeneity, while minimizing the need for animals in drug discovery.</description><identifier>ISSN: 1755-375X</identifier><identifier>EISSN: 1755-3768</identifier><identifier>DOI: 10.1111/aos.16138</identifier><language>eng</language><publisher>Malden: Wiley Subscription Services, Inc</publisher><subject>Acidification ; Aquaporin 4 ; Diabetes mellitus ; Drug discovery ; Drug screening ; Drugs ; Glial fibrillary acidic protein ; Glutamate-ammonia ligase ; Glycolysis ; Immunocytochemistry ; Macular degeneration ; Metabolic flux ; Mitophagy ; Mueller cells ; Oral administration ; PTEN-induced putative kinase ; Retinopathy ; Senescence ; Western blotting</subject><ispartof>Acta ophthalmologica (Oxford, England), 2024-01, Vol.102 (S279), p.n/a</ispartof><rights>2024 The Authors Acta Ophthalmologica © 2024 Acta Ophthalmologica Scandinavica Foundation</rights><rights>Copyright © 2024 Acta Ophthalmologica Scandinavica Foundation</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Faos.16138$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,781,785,1418,27929,27930,45580</link.rule.ids></links><search><creatorcontrib>Anderson, Aidan</creatorcontrib><creatorcontrib>Bouzinab, Kaouthar</creatorcontrib><creatorcontrib>Rudzinska, Paula</creatorcontrib><creatorcontrib>Ganley, Ian</creatorcontrib><creatorcontrib>Wallace, Graham</creatorcontrib><creatorcontrib>Romero, Jose M.</creatorcontrib><title>Mitophagy‐reporter Muller cell line (MQ‐MG2) as a novel platform for ocular drug discovery</title><title>Acta ophthalmologica (Oxford, England)</title><description>Aims/Purpose: The controlled activation of mitophagy has emerged as an exciting therapeutic angle in the treatment of ocular conditions, including diabetic retinopathy and age‐related macular degeneration. Here, we report a novel Muller cell line (MQ‐MG2) for the rapid screening of mitophagy‐activating drugs.
Methods: MQ‐MG2 were cloned from spontaneously immortalized primary Muller cells (PMCs) derived from mitophagy reporter (Mito‐QC) mice. Muller glia characteristics were assessed by immunocytochemistry, western blotting, and metabolic flux (Seahorse). The versatility of MQ‐MG2 to detect mitophagy‐activating drugs was tested via pharmacological activation (PINK1‐dependent and PINK1‐independent) and further validated in vivo using Mito‐QC mice.
Results: MQ‐MG2 were expanded over 50 passages while retaining expression of Mito‐QC reporter. MQ‐MG2 showed key phenotypic markers of Muller glia, including glutamine synthetase, glial fibrillary acidic protein, Aquaporin 4, and Interleukin‐33. At the bioenergetic level, MQ‐MG2 showed lower basal‐ and ATP‐linked respiration than PMCs, while displaying superior reserve capacity (p < 0.001). Indicative of equivalent glycolytic profiles, extracellular acidification rates (baseline and stressed) remained comparable to PMCs. Importantly, MQ‐MG2 showed excellent sensitivity to screen for mitophagy‐activating drugs, including novel small‐molecules acting through (putative) PINK1‐independent pathways. The versatility of MQ‐MG2 as a drug discovery platform was validated in vivo, where oral administration of PINK1‐independent activator (PIA‐01) amplified mitophagy at the outer retina dose‐dependently.
Conclusions: MQ‐MG2 enables rapid and reliable detection of mitophagy‐activating drugs for ocular application. This platform overcomes the limitations of primary cultures, including variability due to cellular senescence and heterogeneity, while minimizing the need for animals in drug discovery.</description><subject>Acidification</subject><subject>Aquaporin 4</subject><subject>Diabetes mellitus</subject><subject>Drug discovery</subject><subject>Drug screening</subject><subject>Drugs</subject><subject>Glial fibrillary acidic protein</subject><subject>Glutamate-ammonia ligase</subject><subject>Glycolysis</subject><subject>Immunocytochemistry</subject><subject>Macular degeneration</subject><subject>Metabolic flux</subject><subject>Mitophagy</subject><subject>Mueller cells</subject><subject>Oral administration</subject><subject>PTEN-induced putative kinase</subject><subject>Retinopathy</subject><subject>Senescence</subject><subject>Western blotting</subject><issn>1755-375X</issn><issn>1755-3768</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp1kMFKxDAQhoMouK4efIOAFz10N9M2bXpcFl2FLYuo4MmQtsnaJbupSav05iP4jD6J0Yo35zD_wHzzD_wInQKZgK-pMG4CCURsD40gpTSI0oTt_8308RAdObchJIEkiUfoKa9b0zyLdf_5_mFlY2wrLc47rb2UUmus653E5_mt3-eL8AILhwXemVepcaNFq4zdYt-wKTstLK5st8ZV7UpP2P4YHSihnTz51TF6uLq8n18Hy9XiZj5bBiVEKQtEWWRMhKCUjEQsqaCMhHEVZRKoquKCxGmVQMiAxJRJkaUAKlakoIUQADKNxuhs8G2seemka_nGdHbnX_KIsCyhACzz1MVAldY4Z6Xija23wvYcCP-Oj_v4-E98np0O7FutZf8_yGeru-HiCw9ectw</recordid><startdate>202401</startdate><enddate>202401</enddate><creator>Anderson, Aidan</creator><creator>Bouzinab, Kaouthar</creator><creator>Rudzinska, Paula</creator><creator>Ganley, Ian</creator><creator>Wallace, Graham</creator><creator>Romero, Jose M.</creator><general>Wiley Subscription Services, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope></search><sort><creationdate>202401</creationdate><title>Mitophagy‐reporter Muller cell line (MQ‐MG2) as a novel platform for ocular drug discovery</title><author>Anderson, Aidan ; Bouzinab, Kaouthar ; Rudzinska, Paula ; Ganley, Ian ; Wallace, Graham ; Romero, Jose M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1378-acb98a21ffe3a4e5a58024d39e15fd4b047d612810458ea9711f4f0b5baa11e73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Acidification</topic><topic>Aquaporin 4</topic><topic>Diabetes mellitus</topic><topic>Drug discovery</topic><topic>Drug screening</topic><topic>Drugs</topic><topic>Glial fibrillary acidic protein</topic><topic>Glutamate-ammonia ligase</topic><topic>Glycolysis</topic><topic>Immunocytochemistry</topic><topic>Macular degeneration</topic><topic>Metabolic flux</topic><topic>Mitophagy</topic><topic>Mueller cells</topic><topic>Oral administration</topic><topic>PTEN-induced putative kinase</topic><topic>Retinopathy</topic><topic>Senescence</topic><topic>Western blotting</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Anderson, Aidan</creatorcontrib><creatorcontrib>Bouzinab, Kaouthar</creatorcontrib><creatorcontrib>Rudzinska, Paula</creatorcontrib><creatorcontrib>Ganley, Ian</creatorcontrib><creatorcontrib>Wallace, Graham</creatorcontrib><creatorcontrib>Romero, Jose M.</creatorcontrib><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><jtitle>Acta ophthalmologica (Oxford, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Anderson, Aidan</au><au>Bouzinab, Kaouthar</au><au>Rudzinska, Paula</au><au>Ganley, Ian</au><au>Wallace, Graham</au><au>Romero, Jose M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mitophagy‐reporter Muller cell line (MQ‐MG2) as a novel platform for ocular drug discovery</atitle><jtitle>Acta ophthalmologica (Oxford, England)</jtitle><date>2024-01</date><risdate>2024</risdate><volume>102</volume><issue>S279</issue><epage>n/a</epage><issn>1755-375X</issn><eissn>1755-3768</eissn><abstract>Aims/Purpose: The controlled activation of mitophagy has emerged as an exciting therapeutic angle in the treatment of ocular conditions, including diabetic retinopathy and age‐related macular degeneration. Here, we report a novel Muller cell line (MQ‐MG2) for the rapid screening of mitophagy‐activating drugs.
Methods: MQ‐MG2 were cloned from spontaneously immortalized primary Muller cells (PMCs) derived from mitophagy reporter (Mito‐QC) mice. Muller glia characteristics were assessed by immunocytochemistry, western blotting, and metabolic flux (Seahorse). The versatility of MQ‐MG2 to detect mitophagy‐activating drugs was tested via pharmacological activation (PINK1‐dependent and PINK1‐independent) and further validated in vivo using Mito‐QC mice.
Results: MQ‐MG2 were expanded over 50 passages while retaining expression of Mito‐QC reporter. MQ‐MG2 showed key phenotypic markers of Muller glia, including glutamine synthetase, glial fibrillary acidic protein, Aquaporin 4, and Interleukin‐33. At the bioenergetic level, MQ‐MG2 showed lower basal‐ and ATP‐linked respiration than PMCs, while displaying superior reserve capacity (p < 0.001). Indicative of equivalent glycolytic profiles, extracellular acidification rates (baseline and stressed) remained comparable to PMCs. Importantly, MQ‐MG2 showed excellent sensitivity to screen for mitophagy‐activating drugs, including novel small‐molecules acting through (putative) PINK1‐independent pathways. The versatility of MQ‐MG2 as a drug discovery platform was validated in vivo, where oral administration of PINK1‐independent activator (PIA‐01) amplified mitophagy at the outer retina dose‐dependently.
Conclusions: MQ‐MG2 enables rapid and reliable detection of mitophagy‐activating drugs for ocular application. This platform overcomes the limitations of primary cultures, including variability due to cellular senescence and heterogeneity, while minimizing the need for animals in drug discovery.</abstract><cop>Malden</cop><pub>Wiley Subscription Services, Inc</pub><doi>10.1111/aos.16138</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1755-375X |
| ispartof | Acta ophthalmologica (Oxford, England), 2024-01, Vol.102 (S279), p.n/a |
| issn | 1755-375X 1755-3768 |
| language | eng |
| recordid | cdi_proquest_journals_3089651189 |
| source | Wiley Online Library All Journals |
| subjects | Acidification Aquaporin 4 Diabetes mellitus Drug discovery Drug screening Drugs Glial fibrillary acidic protein Glutamate-ammonia ligase Glycolysis Immunocytochemistry Macular degeneration Metabolic flux Mitophagy Mueller cells Oral administration PTEN-induced putative kinase Retinopathy Senescence Western blotting |
| title | Mitophagy‐reporter Muller cell line (MQ‐MG2) as a novel platform for ocular drug discovery |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-15T13%3A58%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mitophagy%E2%80%90reporter%20Muller%20cell%20line%20(MQ%E2%80%90MG2)%20as%20a%20novel%20platform%20for%20ocular%20drug%20discovery&rft.jtitle=Acta%20ophthalmologica%20(Oxford,%20England)&rft.au=Anderson,%20Aidan&rft.date=2024-01&rft.volume=102&rft.issue=S279&rft.epage=n/a&rft.issn=1755-375X&rft.eissn=1755-3768&rft_id=info:doi/10.1111/aos.16138&rft_dat=%3Cproquest_cross%3E3089651189%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3089651189&rft_id=info:pmid/&rfr_iscdi=true |